Impact of Myositis in Scleroderma Patients Systemic sclerosis (SSc) may have overlap features such as myositis. When present, myositis in SSc is associated with an increased risk of cardiac involvement and a shift in mortality away from ILD towards a greater cardiac risk. https://t.co/bKYP9FmadY

“It’s also critically important to take the GI tract into consideration” – Dr. Joshua Steinberg, Gastroenterologist Watch to learn how GI symptoms can signal a need for coordinated care in PsA. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/rp2e5oknVF https://t.co/c9nScljxQt

EBR Journal Club: Secukinumab in Polymyalgia Rheumatica (REPLENISH) The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal to an important RCT in rheumatology. https://t.co/uejuXKsrWD https://t.co/SqtsxK6etR

150 #Gout pts (56 yrs old; 33wks F/U; 21% drank EtOH, 29% obese, 5% MASLD) on allopurinol followed w/ labs. 30y (20%) had incr AST/ALT (87% mild, none severe). Allopurinol was cont 18/10 without change in AST/ALT. Allopurinol was not the primary cause of LFT elevation https://t.co/XOkUtbdRIK

Monogenic Inflammatory Disorders Go Unrecognized Lancet Rheumatology published a large cohort analysis using a genome-first approach with whole-exome sequencing, finding a prevalence of 1 in 4026 (159/640092) for monogenic disorders, half with inflammatory features. Only one https://t.co/bItqMXIoUH

Treat-to-Target has Excellent 10-Year Outcomes in RA Most patients with RA whose initial treatment used a stringent treat-to-target strategy in a clinical trial were in remission 10 years later, with only modest radiographic progression over that time, researchers said. https://t.co/aWQgQAsoSI

Should You Use Low Dose Naltrexone? A recent review of 105 studies and 15 randomized controlled trials of LDN found that, across a range of disorders (chronic pain, autoimmune and neuroimmune disorders, gastrointestinal disease, dermatological conditions, post-infectious https://t.co/sC7kteQVMZ

Cryptococcus is rare, but twice as likely with JAK inhibitors. Retrospective TriNetX analysis of RA pts (>30k/grp) starting JAKi vs TNFi; JAKi vs non-TNFi; & TNFi vs non-TNF. Crypto seen in <0.2% in all groups; but signif higher HR for JAKi (HR 2.2 & 2.15) https://t.co/1J4SjcqF8u

REVEAL study enrolled 418 early microscopic polyangiitis pts - High baseline (Pre-Rx) neutrophil-to-lymphocyte ratio (NLR > 10) was assoc w/ signif higer Dz activity (BVAS), alveolar hemorrhage, poor renal function, reduced survival & higher infection-related mortality (P = https://t.co/wYBOz00GGB

FDA has granted Fast Track designation to EG-501 (Evergreen), investigational Rx for cognitive impairment with neuropsychiatric systemic lupus erythematosus (NPSLE), following positive results from the phase 2 ClearMEMory study https://t.co/n9wO2wLLBk https://t.co/E0kL3j931Z

Biologic safety. Vasculitis mimics. What to do with seropositive arthralgia. RheumNow Live 2027 tackles the decisions you face in clinic. Jan. 30–31 | Onsite + virtual Registration NOW OPEN. Early Bird Pricing through 12/15/2026. https://t.co/zYYC2350tE https://t.co/mPI1o7sEcx

Treat-to-Target has Excellent 10-Year Outcomes in RA Most patients with RA whose initial treatment used a stringent treat-to-target strategy in a clinical trial were in remission 10 years later, with only modest radiographic progression over that time, researchers said. https://t.co/sFI67Wo2fK

Monogenic Inflammatory Disorders Go Unrecognized Lancet Rheumatology published a large cohort analysis using a genome-first approach with whole-exome sequencing, finding a prevalence of 1 in 4026 (159/640092) for monogenic disorders, half with inflammatory features. Only one https://t.co/4v1PP41rii

Joint Disease in SLE Reconsidered A new Frontiers in Immunology review from Ong, Wincup and colleagues, shows that lupus arthropathy is not a single uniform entity and it is biologically under-studied and clinically mismeasured, Moreover, the biology of lupus arthritis may https://t.co/M5m6TMZr3x